ENABLE: third-generation anti-CD19 CAR for R/R NHL
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2023-05-04
Просмотров: 74
Описание:
Robert Weinkove, MA (Cantab), MBBS (Hons), PhD, FRACP, FRCP, Malaghan Institute of Medical Research, Wellington, New Zealand, gives an update on the ongoing ENABLE trial (NCT04049513). The Phase I escalation study aims to identify a safe dose of third-generation anti-CD19 CAR T-Cells (WZTL-002) in the treatment of patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Dr Weinkove highlights the lack of neurotoxicity observed amongst the treated cohort. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
